Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in SDH-Deficient Advanced GIST
NCT05661643Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in gastrointestinal stromal tumor (GIST), sponsored by Asan Medical Center. Primary endpoint: Objective Response Rate up to 4 years. Started Jun 2023; status: recruiting.
02
Drugs
temozolomide
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05661643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661643.